|
|
“DESIGN,
DEVELOPMENT and
OPTIMIZATION of ANTIBODIES for
RESEARCH TOOLS and THERAPEUTICS” |
Overview
Despite many years of set-backs, the goal of antibodies as “magic bullets” for the treatment of human disease is beginning to be met. This conference focuses on the latest research, technologies and applications of antibodies in therapeutics and diagnostics.
Opening Presentation: Regulatory Issues
REGULATORY UPDATE: Latest FDA Initiatives Related to Monoclonal Antibodies
Posttranslational Modifications of
mAbs: More Than Meets the Eye
Protein Formulation of an IgG1 Antibody with Atypical Glycosylation: A Study on the Stability of its Glycoforms
Immunogenicity Assessment of Novel Therapeutic Antibodies
|
Monoclonal Antibody Development to
Biothreat, Foreign Animal Disease Agents and Emerging Infectious Agents
Human Monoclonal Antibodies against Viral Hepatitis: Potential Treatment to Prevent HCV Re-Infection in Liver Transplant Patients
|
|
Antibody
Therapeutics: Part II
|
Selection and Development of a Cocktail of Monoclonal Antibodies for Use in Post-Exposure Prophylaxis of Rabies
Potential of Tumor Muc 1 Recognizing Antibody Pankomabtm
Yeast-Based Production of Therapeutic Glycoproteins with Uniform Human-Like
Glycans: A Discovery Tool for Therapeutic Antibodies with Increased Potency
|
|
Scientific Advisory Board
|
Dr. Hennie Hoogenboom, Merus BV
Dr. Peter Hudson, CSIRO-Australia
Dr. Lutz Jermutus, Cambridge Antibody Technology Ltd.
Dr. Sachdev Sidhu, Genentech, Inc.
Dr. Arne Skerra, Technical University Munich
|
Call for Sponsors and Exhibitors
Showcase your company’s expertise, brand your solutions and develop revenue opportunities with qualified
decision-makers
by becoming an Exhibitor or Sponsor of PEGS: The Protein Engineering Summit. We have a number of
opportunities available, including 30-minute technology workshop presentations. To discuss sponsoring or exhibiting at this conference, please contact Carol
Dinerstein at 781-972-5471 or dinerstein@healthtech.com.
|
